CD8A and neoplasm: Since we showed that the NFATc1 inhibitor CsA treatment significantly decreased the mRNA levels and surface expression of PD-1 in wild-type CD8+ CTLs (Fig3D), we tested whether in vitro targeting NFATc1 in CD8+ CTLs could increase anti-tumor responses.